What is the clinical evidence from this study?

Population: Atherosclerosis. Intervention: Angiotensin II. Primary outcome: Premature senescence of vascular smooth muscle cells and development of atherosclerosis.

What question did this study set out to answer?

This study investigates the role of Angiotensin II in inducing premature senescence in vascular smooth muscle cells and its relation to atherosclerosis.

August 15, 2006Circulation

Angiotensin II Induces Premature Senescence of Vascular Smooth Muscle Cells and Accelerates the Development of Atherosclerosis via a p21-Dependent Pathway

Q: What are the key findings of this study?

Angiotensin II promotes vascular inflammation and accelerates atherosclerosis by inducing premature senescence of vascular smooth muscle cells via a p21-dependent pathway.

View Full Paper

Ask AI

Bookmark

Key result

Angiotensin II accelerates atherosclerosis by driving vascular smooth muscle cell senescence via p21.

Why the study?

The effects of angiotensin II on vascular smooth muscle cell senescence and its role in atherosclerosis pathogenesis had not been examined.

Does Angiotensin II induce premature senescence of VSMCs and accelerate atherosclerosis via a p21-dependent pathway?

Key Points

This study investigates the role of Angiotensin II in inducing premature senescence in vascular smooth muscle cells and its relation to atherosclerosis.
Human vascular smooth muscle cells were treated with Angiotensin II to assess senescence and inflammatory markers via the p53/p21 pathway in vitro.
A mouse model of atherosclerosis was used to evaluate the effects of Ang II on vascular cell senescence and inflammation, including p21 expression.
The impact of p21 deficiency on the development of atherosclerosis was analyzed by replacing p21-deficient bone marrow cells with wild-type cells.
Ang II significantly induced premature senescence in VSMCs through the p53/p21 pathway (p<0.05).
In the mouse model, Ang II increased senescent VSMCs and proinflammatory molecule expression, with a marked elevation in p21 levels (p<0.01).
Loss of p21 reduced proinflammatory responses to Ang II, inhibiting atherosclerosis progression effectively.

Structured PICO

Does Angiotensin II induce premature senescence of VSMCs and accelerate atherosclerosis via a p21-dependent pathway?

Population

Human vascular smooth muscle cells (VSMCs) in vitro and a mouse model of atherosclerosis (including p21-deficient mice and bone marrow chimeras)

Intervention

Angiotensin II (Ang II)

Comparator

Control / p21-deficient models

Outcome

Premature senescence of VSMCs and development of atherosclerosissurrogate

Angiotensin II promotes vascular inflammation and atherosclerosis by inducing premature senescence of vascular smooth muscle cells via a p21-dependent pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Does not support p21-targeted therapy in patients; hypothesis-generating for Ang II-driven vascular senescence in humans.

Cite This Study

Kunieda et al. (2006) studied Atherosclerosis. Angiotensin II was evaluated on Premature senescence of vascular smooth muscle cells and development of atherosclerosis. Angiotensin II promotes vascular inflammation and accelerates atherosclerosis by inducing premature senescence of vascular smooth muscle cells via a p21-dependent pathway.

synapsesocial.com/papers/6a2bcb24ee61e29454f86396 https://doi.org/10.1161/circulationaha.106.626606

View Full Paper

Ask AI

Bookmark

Angiotensin II Induces Premature Senescence of Vascular Smooth Muscle Cells and Accelerates the Development of Atherosclerosis via a p21-Dependent Pathway

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Angiotensin II Induces Premature Senescence of Vascular Smooth Muscle Cells and Accelerates the Development of Atherosclerosis via a p21-Dependent Pathway

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider